Copyright: ©Author(s) 2026.
World J Clin Cases. Jun 16, 2026; 14(17): 118087
Published online Jun 16, 2026. doi: 10.12998/wjcc.v14.i17.118087
Published online Jun 16, 2026. doi: 10.12998/wjcc.v14.i17.118087
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analysis flowchart of the included studies.
1Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers). 2If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.
Figure 2 Forest plot of subgroup analysis of venous thromboembolism by regimen type.
RR: Risk ratio; CI: Confidence interval.
Figure 3 Forest plot of deep venous thrombosis.
RR: Risk ratio; CI: Confidence interval.
Figure 4 Forest plot of subgroup analysis of clinically relevant non-major bleeding by regimen type.
RR: Risk ratio; CI: Confidence interval.
- Citation: Haider F, Ahmed F, Junaid Y, Khalid M, Dar A, Arham M, Ullah A, Aliha S, Arshad MU, Naeem K, Ali Hashim MM, Gohar N, Ricciuti A, Bhanderi V, Alenezi F, Patel B. Direct oral anticoagulants vs low-molecular-weight heparins for cancer-associated thromboembolism. World J Clin Cases 2026; 14(17): 118087
- URL: https://www.wjgnet.com/2307-8960/full/v14/i17/118087.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v14.i17.118087